Inside the Engine Room of Trial Innovation with Paullette Azar-Tannous, Sonic Clinical Trials

About the Interviewee

Paullette Azar-Tannous is the Chief Executive Officer of Sonic Clinical Trials.

Paullette Azar-Tannous, B.Sc. BiomedSci, MBA, GAICD, is Chief Executive Officer of Sonic Clinical Trials, a leading global provider of integrated laboratory services for the pharmaceutical and biotechnology sectors. With over 30 years of executive leadership across Australia, Asia Pacific, Europe, and the United States, she oversees strategic and operational delivery of complex clinical trial programs, enabling clients to accelerate drug development with scientific precision, operational excellence, and global consistency.

Paullette holds a Bachelor of Biomedical Science from the University of Technology Sydney, a Master of Business Administration from Charles Sturt University, and is a Graduate of the Australian Institute of Company Directors (GAICD). Her expertise spans regulated laboratory systems, clinical trial infrastructure, stakeholder engagement, crisis and risk management, ESG leadership, and organizational transformation—underpinned by a commitment to scientific integrity and patient-centered outcomes.

She began her career as a Medical Scientist at Douglass Hanly Moir and quickly advanced through leadership roles at Covance and Sonic Healthcare, including Laboratory Manager, Business Development Manager, and General Manager. Since her appointment as CEO in 2017, she has led Sonic Clinical Trials through a period of sustained growth, global expansion, and digital innovation—successfully establishing operations in Australia, Singapore, Belgium, and the United States.

A strategic leader who blends technical insight with commercial acumen, Paullette has shaped global laboratory networks, pioneered quality and systems development, and championed talent development within multidisciplinary teams. Her people-first leadership style and track record of delivering clinical research solutions across regulatory environments make her a respected figure in the life sciences sector.

Beyond her corporate role, Paullette is a passionate advocate for ethical, efficient, and scalable clinical research. She regularly advises on governance frameworks, regulatory compliance, and workforce capability building, and is committed to advancing the role of laboratory science in driving healthcare innovation globally.

The Discussion

From Vision to Leadership: The Genesis of Sonic Clinical Trials

[Dex Marco]: It’s such a pleasure to have you here with us, Ms. Paullette. Your career has spanned diverse facets of biomedical science and business, culminating in the founding and leadership of Sonic Clinical Trials. Can you walk us through your journey to establishing Sonic Clinical Trials and how your background in biomedical science and executive leadership helped shape its mission and model?

[Paullette]: Thank you for having me here, Dex. The journey to establishing Sonic Clinical Trials has been both professionally rewarding and personally meaningful. My career began in biomedical science, working hands-on in hospital pathology and clinical laboratory environments.

That scientific foundation gave me an early and deep appreciation for the rigor, quality, and precision that underpin healthcare decisions and drug development. Over the years, I transitioned into leadership roles across laboratory operations, quality assurance, client services, and business development spanning Australia, Asia Pacific, Europe, and the US. That blend of science and strategy shaped not only how I viewed the industry, but also where I saw the gaps.

Sonic Clinical Trials was born out of a clear vision: to create a central laboratory partner that understands the operational complexity of clinical trials, but also prioritizes quality, service, and local insight – all while operating at a global scale. We saw an opportunity to leverage the strength of the Sonic Healthcare network – one of the world’s leading diagnostic providers – and build a model that is nimble, scientifically driven, and globally harmonized.

Our mission from day one has been to deliver reliable, high-quality laboratory data that enables confident decision-making in clinical research. But beyond data, we have built a culture of collaboration – partnering closely with sponsors, CROs, and investigators to truly support the success of every trial.

In many ways, my background allowed me to connect the dots – between science and service, between local capability and global consistency, and between operational execution and long-term partnerships. This is what continues to shape Sonic Clinical Trials today.

Central Labs as Strategic Enablers of Drug Development

[Dex]: Centralized laboratory networks are increasingly seen as critical infrastructure in accelerating trial timelines and standardizing outcomes. How is Sonic Clinical Trials positioning its central lab capabilities to optimize drug development speed, reliability, and global operational consistency?

[Paullette]: Sonic Clinical Trials is uniquely positioned to optimize drug development through speed, reliability, and global operational consistency by leveraging the full strength of our integrated diagnostic network across Australia, New Zealand, Europe, and the United States.

We have built a central lab model that combines scientific excellence with deep operational know-how. Our approach focuses on these three key pillars – speed, reliability, and global consistency.

Speed. We reduce study start-up timelines by offering seamless project management, harmonized SOPs, and access to local regulatory intelligence. With labs strategically located across regions and supported by centralized logistics and supply chain solutions, we enable fast sample processing and data turnaround – critical for accelerating trial milestones.

Reliability. Our laboratories are accredited and operate to the highest quality standards (including GCP,GCLP & ISO), ensuring data integrity and compliance from sample collection to reporting. We also deploy highly trained scientific teams who manage assay validation, troubleshooting, and sponsor engagement throughout the trial lifecycle.

Global Consistency. Through our central, unified CTMS and LIMS platform – Artemis, harmonized test menus, standardized collection kits and centralized project oversight, we provide sponsors with consistent, comparable data across countries. Our global footprint allows us to support both regional trials and complex multinational studies without compromising quality or agility.

Ultimately, our goal is to serve as a trusted partner in drug development – delivering results that are not only scientifically sound, but also operationally dependable, wherever in the world the trial takes place.

Leveraging Digital Innovation in Trial Execution

[Dex]: With the complexity of modern trials, real-time visibility and intelligent data flow are essential. What technologies and digital strategies is Sonic investing in to enhance specimen tracking, data transparency, and overall clinical trial integrity?

[Paullette]: At Sonic Clinical Trials, we recognize that the future of clinical research depends on intelligent, connected systems and we are investing accordingly.

Our digital strategy is centered on enabling real-time visibility, enhancing specimen traceability, and ensuring data integrity from collection to reporting. A few core areas of investment include:

Advanced Specimen Tracking.
We have implemented a real-time tracking solution Sonic Realtime® that follows specimens from collection through to analysis and data release. This system integrates directly with our laboratory information management system (LIMS) and is accessible to clients via secure portals, providing full visibility of sample status and location at every step.

Harmonized Global LIMS Platform.
Our central labs operate on a unified, validated LIMS that allows for standardized test panels, consistent reporting formats, and seamless data exchange across geographies. This harmonization is critical to maintaining consistency and comparability in global trials, especially those involving multiple time zones and regulatory jurisdictions.

Digital Data Portals and Dashboards.
We offer clients on-demand access to lab data, KPIs, and quality metrics through dashboards. These tools support proactive decision-making, faster issue resolution, and enhanced sponsor oversight -without compromising data security or compliance.

AI-Enabled Data Oversight (in pilot stages).
We are actively exploring AI-driven tools for improving diagnostic accuracy, trend monitoring, flagging protocol deviations, and forecasting logistical risks. These solutions are designed to further enhance our ability to detect and address issues before they impact study timelines or data quality.

For us, digital innovation is about building smarter, more responsive systems that uphold the scientific and regulatory standards our sponsors rely on. Ultimately, our goal is to make clinical trial execution more transparent, predictable, and globally coordinated.

Partnering for Flexible, Patient-Centric Trial Models

[Dex]: The rise of adaptive and decentralized trials demands more agile and collaborative laboratory frameworks. How does Sonic Clinical Trials work with sponsors to design lab solutions that enable trial decentralization while preserving scientific robustness?

[Paullette]: At Sonic Clinical Trials, we view the rise of decentralized and adaptive trial models as an opportunity to reimagine how laboratory services can better support patient-centric research without compromising scientific integrity.

Our approach is grounded in flexibility, collaboration, and quality. We partner closely with sponsors from the outset to design lab frameworks that align with the trials scientific goals while accommodating evolving trial designs, diverse site geographies, and participant convenience.

Here’s how we do it:

Integrated Local and Global Lab Network.
We leverage Sonic Healthcare’s global footprint of accredited laboratories to provide localized support for specimen collection, analysis and sample processing, reducing patient and site burden while ensuring rapid turnaround times. This decentralization at the lab level maintains consistency through harmonized SOPs, validated test methods, and centralized data oversight.

At-Home and Remote Collection Solutions.
We work with sponsors and logistics providers to support remote sample collection, including at-home phlebotomy and mobile kits. These services are integrated with our central lab workflows to ensure sample integrity, chain of custody, and regulatory compliance are never compromised.

Custom Lab Kits and Logistics Coordination.
For adaptive trial designs, we offer agile lab kit production and inventory tracking, enabling fast protocol amendments and global distribution. Our team proactively manages logistics, anticipating changes in patient enrolment patterns and regional supply needs which is especially critical in decentralized settings.

Data Consistency and Oversight.
Using the Sonic Local lab or Sonic Lab Merge solution, all lab data is captured in real time via our centralized LIMS and made available to sponsors through our secure digital portal Sonic Realtime ®. This allows for full transparency, supports adaptive decision-making, and ensures data harmonization even when samples are collected from varied sources.

Ultimately, we design lab solutions that evolve with the trial. Whether it is supporting hybrid models, regional collection hubs, or fully decentralized protocols, our priority is to protect scientific quality while enabling flexibility, better patient access leads to better trial outcomes.

Operationalizing Excellence: Quality, Compliance, and Therapeutic Expertise

[Dex]: Regulatory scrutiny and scientific complexity require unwavering quality and domain-specific insight. What are the key strategies Sonic Clinical Trials employs to uphold global quality standards and provide scientific leadership across therapeutic areas?

[Paullette]: At Sonic Clinical Trials, operational excellence is a requirement. In an environment where regulatory expectations are intensifying and clinical trial designs are becoming more complex, our strategy is built on three core pillars: global quality standards, scientific expertise by therapeutic depth, meticulous risk management, and continuous improvement.

Global Quality Systems.
We operate under a harmonized Quality Management System (QMS) aligned with international GCP, GLP, and ISO standards. Across our global laboratory network, we maintain rigorous SOPs, regular audits, CAP, UKAS, BELAC and NATA accreditations, and robust staff training programs to ensure every site delivers to the same high standards. Our quality team works proactively to anticipate regulatory trends and implement best practices across all regions.

Scientific Expertise by Therapeutic Area.
Our laboratories are medically led and hence clinical leadership is at the core: ensuring patient care, diagnostic accuracy, and scientific integrity are prioritized. Sonic Healthcare employs over 1,400 specialist pathologists across its global network, many of whom are leaders in their respective therapeutic fields. Their deep clinical insight and diagnostic expertise present a unique opportunity for pharmaceutical partners to strengthen protocol design, biomarker strategies, and scientific oversight throughout the drug development process. We also employ highly experienced medical scientists, and PhD-level experts who provide real-time guidance throughout study lifecycles. We align our scientific oversight with the specific needs of the protocol – whether it’s oncology, infectious diseases, CNS, or metabolic disorders. This ensures assay selection, validation, and troubleshooting are scientifically sound.

Dedicated Study Governance and Risk Management.
Every study is supported by a multidisciplinary project team that includes quality, operational, and scientific input. We apply formal risk-based approaches to identify potential compliance challenges early, particularly in complex or adaptive protocols. We also work closely with sponsors and CROs to ensure that laboratory operations are fully aligned with study data integrity and submission requirements.

Continuous Improvement and Innovation.
We invest in ongoing capability building, not just through technology, but through scientific partnerships, training, and feedback loops from trial execution. Our scientists routinely participate in global forums and cross-lab working groups to ensure we are contributing to, and learning from, the evolving clinical landscape. We combine a disciplined quality culture with deep therapeutic expertise to deliver lab services that sponsors can rely on, not only to meet regulatory demands but to support confident, data-driven decisions across every phase of development.

Leading Global Teams with Purpose and Precision

[Dex]: Scaling globally while maintaining culture and accountability is no small feat in clinical trial operations. Can you share how you approach leadership, talent development, and team performance across Sonic’s international lab footprint?

[Paullette]: Leading a global team at Sonic Clinical Trials requires a clear purpose, strong values, and a commitment to precision in execution, all grounded in a culture of collaboration and continuous development. Our leadership philosophy centers on empowering people, fostering accountability, and nurturing talent across every level of the organization.

We make sure every team member understands how their work directly impacts patient outcomes and drug development globally. This shared purpose drives engagement, commitment, and a collective sense of responsibility. While maintaining global standards, we also trust and equip our regional leaders with the autonomy to adapt operations to local regulations, client needs, and cultural nuances. This balance supports agility without sacrificing consistency.

We priorities ongoing training, mentoring, and career pathways – both scientific and operational – identifying high-potential individuals early and providing them with the skills and opportunities to grow as future leaders. Transparent communication and regular check-ins help maintain open channels across sites and teams. Clear performance metrics and feedback mechanisms allow us to track progress and align teams with common goals.

Finally, we believe that recognizing success, promoting diversity, and ensuring every voice is heard are essential to sustaining motivation and fostering innovation within a complex, distributed environment. By combining these elements, Sonic Clinical Trials not only scales effectively but does so with a cohesive culture that upholds quality, accountability, and scientific excellence, no matter where our teams are located.

Looking Ahead: Vision and Strategic Priorities for Sonic Clinical Trials

[Dex]: The landscape of clinical development continues to evolve rapidly amid regulatory, technological, and patient-centric shifts. As CEO, what is your forward-looking vision for Sonic Clinical Trials, and which strategic priorities will define your roadmap for innovation and growth in the coming years?

[Paullette]: My vision for Sonic Clinical Trials is to be the central laboratory partner of choice for global drug development – not just because of our scientific quality, but because of our ability to adapt, innovate, and deliver with consistency across every region we serve. We are building a model that combines the depth of a medically led organization with the operational sophistication and digital tools needed for todays complex trial landscape.

Our strategic priorities in the years ahead are clear.

First, we are expanding our global laboratory footprint and harmonizing systems to ensure end-to-end quality, scalability, and real-time data access for sponsors, whether they are running a single-country study or a multinational program. We will continue to invest in digital infrastructure, including advanced specimen tracking, connected LIMS platforms, and AI-enabled analytics, to enable faster decisions and greater visibility across the trial lifecycle.

Second, we are embracing the shift toward decentralized and adaptive trial designs by offering lab solutions that are more flexible and patient accessible – such as mobile phlebotomy, regional processing hubs, and remote sample handling, while maintaining scientific rigor and regulatory
compliance.

Third, we are reinforcing our commitment on therapeutic expertise. Our team of over 1,400 specialist pathologists and thousands of scientists globally brings deep domain knowledge that we are continuing to mobilize in support of complex protocols, biomarker development, and precision medicine strategies. We will further strengthen this capability to provide not just services, but trusted scientific leadership.

And finally, we are cultivating a culture of excellence, investing in our people, our leadership pipeline, and cross-functional collaboration to ensure that we remain responsive, resilient, and trusted by our clients.

Sonic Clinical Trials is not standing still. We are deliberately building a future-ready, globally connected central lab that advances drug development and delivers results – to sponsors, investigators, and most importantly, patients.

As CEO, I am excited to lead that journey into the future.

Engr. Dex Marco Tiu Guibelondo, B.Sc. Pharm, R.Ph., B.Sc. CpE

Editor-in-Chief, PharmaFEATURES

Join Proventa International’s Clinical Operations and Clinical Trial Supply Chain Europe Strategy Meeting at Crowne Plaza London Docklands, London, United Kingdom on the 9th of October 2025 to learn more about Sonic Clinical Trials Pty Ltd.